These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27549635)

  • 1. West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia.
    Dieye B; Affara M; Sangare L; Joof F; Ndiaye YD; Gomis JF; Ndiaye M; Mbaye A; Diakite M; Sy N; Mbengue B; Deme AB; Daniels R; Ahouidi AD; Dieye T; Abdullahi A; Doumbia S; Ndiaye JL; Diarra A; Ismaela A; Coulibaly M; Welty C; Ngwa AA; Shaffer J; D'Alessandro U; Volkman SK; Wirth DF; Krogstad DJ; Koita O; Nwakanma D; Ndiaye D
    Am J Trop Med Hyg; 2016 Nov; 95(5):1054-1060. PubMed ID: 27549635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.
    Otienoburu SD; Maïga-Ascofaré O; Schramm B; Jullien V; Jones JJ; Zolia YM; Houzé P; Ashley EA; Kiechel JR; Guérin PJ; Le Bras J; Houzé S
    Malar J; 2016 Sep; 15(1):452. PubMed ID: 27596849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained
    Amambua-Ngwa A; Okebe J; Mbye H; Ceesay S; El-Fatouri F; Joof F; Nyang H; Janha R; Affara M; Ahmad A; Kolly O; Nwakanma D; D'Alessandro U
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
    Venkatesan M; Gadalla NB; Stepniewska K; Dahal P; Nsanzabana C; Moriera C; Price RN; Mårtensson A; Rosenthal PJ; Dorsey G; Sutherland CJ; Guérin P; Davis TME; Ménard D; Adam I; Ademowo G; Arze C; Baliraine FN; Berens-Riha N; Björkman A; Borrmann S; Checchi F; Desai M; Dhorda M; Djimdé AA; El-Sayed BB; Eshetu T; Eyase F; Falade C; Faucher JF; Fröberg G; Grivoyannis A; Hamour S; Houzé S; Johnson J; Kamugisha E; Kariuki S; Kiechel JR; Kironde F; Kofoed PE; LeBras J; Malmberg M; Mwai L; Ngasala B; Nosten F; Nsobya SL; Nzila A; Oguike M; Otienoburu SD; Ogutu B; Ouédraogo JB; Piola P; Rombo L; Schramm B; Somé AF; Thwing J; Ursing J; Wong RPM; Zeynudin A; Zongo I; Plowe CV; Sibley CH; Asaq Molecular Marker Study Group
    Am J Trop Med Hyg; 2014 Oct; 91(4):833-843. PubMed ID: 25048375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing Antimalarial Drug Sensitivities in Uganda.
    Rasmussen SA; Ceja FG; Conrad MD; Tumwebaze PK; Byaruhanga O; Katairo T; Nsobya SL; Rosenthal PJ; Cooper RA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India.
    Bharti PK; Shukla MM; Ringwald P; Krishna S; Singh PP; Yadav A; Mishra S; Gahlot U; Malaiya JP; Kumar A; Prasad S; Baghel P; Singh M; Vadadi J; Singh MP; Bustos MD; Ortega LI; Christophel EM; Kashyotia SS; Sonal GS; Singh N
    Malar J; 2016 Oct; 15(1):498. PubMed ID: 27737665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.
    Price RN; Uhlemann AC; van Vugt M; Brockman A; Hutagalung R; Nair S; Nash D; Singhasivanon P; Anderson TJ; Krishna S; White NJ; Nosten F
    Clin Infect Dis; 2006 Jun; 42(11):1570-7. PubMed ID: 16652314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia.
    Lim P; Alker AP; Khim N; Shah NK; Incardona S; Doung S; Yi P; Bouth DM; Bouchier C; Puijalon OM; Meshnick SR; Wongsrichanalai C; Fandeur T; Le Bras J; Ringwald P; Ariey F
    Malar J; 2009 Jan; 8():11. PubMed ID: 19138391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine].
    Sow D; Ndiaye JL; Sylla K; Ba MS; Tine RC; Faye B; Pene M; Ndiaye M; Seck A; Lo AC; Abiola A; Dieng Y; Gaye O
    Med Sante Trop; 2016; 26(1):45-50. PubMed ID: 26644184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of
    Maiga H; Grivoyannis A; Sagara I; Traore K; Traore OB; Tolo Y; Traore A; Bamadio A; Traore ZI; Sanogo K; Doumbo OK; Plowe CV; Djimde AA
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
    Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
    Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the therapeutic efficacy of artemether-lumefantrine for uncomplicated malaria in Lagos, Nigeria: a comprehensive study on treatment response and resistance markers.
    Oyebola KM; Ligali FC; Owoloye AJ; Aina OO; Alo YM; Erinwusi B; Olufemi MJ; Salako BL
    Malar J; 2024 Aug; 23(1):261. PubMed ID: 39210367
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Montenegro M; Neal AT; Posada M; De Las Salas B; Lopera-Mesa TM; Fairhurst RM; Tobon-Castaño A
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India.
    Valecha N; Srivastava P; Mohanty SS; Mittra P; Sharma SK; Tyagi PK; Pradhan K; Dev V; Singh R; Dash AP; Sharma YD
    Malar J; 2009 May; 8():107. PubMed ID: 19454000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola.
    Kiaco K; Teixeira J; Machado M; do Rosário V; Lopes D
    Malar J; 2015 Dec; 14():504. PubMed ID: 26670642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012-2013.
    Dorkenoo AM; Yehadji D; Agbo YM; Layibo Y; Agbeko F; Adjeloh P; Yakpa K; Sossou E; Awokou F; Ringwald P
    Malar J; 2016 Jun; 15():331. PubMed ID: 27334876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy.
    Warsame M; Hassan AH; Hassan AM; Arale AM; Jibril AM; Mohamud SA; Barrette A; Muse AY; Yusuf FE; Nada RA; Amran JG
    Trop Med Int Health; 2017 Apr; 22(4):415-422. PubMed ID: 28151566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.
    Balikagala B; Mita T; Ikeda M; Sakurai M; Yatsushiro S; Takahashi N; Tachibana SI; Auma M; Ntege EH; Ito D; Takashima E; Palacpac NM; Egwang TG; Onen JO; Kataoka M; Kimura E; Horii T; Tsuboi T
    Malar J; 2017 Jan; 16(1):23. PubMed ID: 28068997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial.
    Koita OA; Sangaré L; Miller HD; Sissako A; Coulibaly M; Thompson TA; Fongoro S; Diarra Y; Ba M; Maiga A; Diallo B; Mushatt DM; Mather FJ; Shaffer JG; Anwar AH; Krogstad DJ
    Lancet Infect Dis; 2017 Dec; 17(12):1266-1275. PubMed ID: 28916443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.